Physician profile
Andrew Kees
NPI 1689674210
$575.26
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $116.56 | 2019-2020 | |
| Amgen INC. | $93.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $80.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.98 | 2019-2020 | |
| Gilead Sciences, INC. | $38.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.21 | 2019 | |
| Akcea Therapeutics, INC. | $17.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.22 | 2019 | |
| Pfizer INC. | $13.61 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.15 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.